Scarica l'app Stockscreener
26.93
3.38%
0.88
Dopo l'orario di chiusura:
26.78
-0.15
-0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$26.05
Aprire:
$26.285
Volume 24 ore:
10.09M
Relative Volume:
0.97
Capitalizzazione di mercato:
$10.41B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.0848
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+0.79%
1M Prestazione:
-3.20%
6M Prestazione:
-37.46%
1 anno Prestazione:
-81.79%
Intervallo 1D:
$25.76
$27.15
Intervallo di 1 settimana:
$25.55
$27.85
Portata 52W:
$23.15
$158.82
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.93 | 10.33B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Lazard Asset Management LLC Sells 11,516 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS cancels Moderna’s $590 million contract for bird flu vaccine - WyomingNews.com
Trump administration pulls bird flu, other vaccine funding awarded to Moderna - CBS News
HHS cancels Moderna bird flu vaccine contract - The Iola Register
Moderna at Bernstein Conference: Strategic Diversification Plans - Investing.com
Is Moderna Stock A Sell After RFK Jr. Yanks Its Bird Flu Vaccine Funding? - Investor's Business Daily
HHS terminates Moderna contract to develop bird flu vaccine - BioPharma Dive
HHS terminates Moderna’s funding for bird flu vaccine, calls mRNA 'under-tested' - The Business Journals
Transcript : Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10 - marketscreener.com
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot - Yahoo Finance
Moderna Is Imperiled by Kennedy’s Health Department. It May Run Out of Cash. - Barron's
Trump administration cancels $766 million Moderna contract to fight future pandemics, including bird flu - NBC News
U.S. Ends $600M Moderna Bird Flu Vaccine Contract - HomeTown Register
HHS cancels $590 million contract with Moderna for bird flu vaccine - WAPT
HHS, led by vaccine skeptic RFK Jr., cancels contract to fight flu viruses - LiveNOW from FOX
Moderna: positive results for H5 avian influenza vaccine - marketscreener.com
Moderna (MRNA) Faces Uncertainty After $766M Contract Termination - GuruFocus
Trump administration cancels $766 million contract with Moderna to develop vaccine against pandemic flu viruses - Fortune
Moderna Loses $760M+ Government Bird Flu Contract as Vaccine Uncertainties Mount - BioSpace
Big blow to Moderna vaccine projects as Trump cancels over $700 million funding - The Economic Times
Trump administration yanks Moderna's bird flu vaccine research funding even as company reports promising test results - CBS News
Moderna stock steady as HHS ends vaccine contract (MRNA:NASDAQ) - Seeking Alpha
Trump Team Pulls $766M Funding Plug on Moderna’s Bird Flu Vaccine - TipRanks
Moderna’s H5 avian flu vaccine shows promise in early trial By Investing.com - Investing.com South Africa
US cancels $766 million pandemic flu vaccine support to Moderna - India Today
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort - Benzinga
Trump admin cancels $766m Moderna contract to fight pandemic flu - MSN
US cancels $590 million contract with Moderna for bird flu shot - Medical Xpress
US cancels $700m in funding for Moderna's bird flu vaccine - The Express Tribune
Trump administration cancels $766 million Moderna contract to fight pandemic flu - MSN
Moderna Says Investigational Influenza Vaccine Boosts Immunity; US Government to Terminate Funding - marketscreener.com
US cancels more than $700 million funding for Moderna bird flu vaccine - Reuters
Woodline Partners LP Purchases 10,968 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
U.S. Government cancels $766 million Moderna contract to fight pandemic flu - The Hindu
Moderna, Inc. (MRNA) Reports Strong H5 Avian Flu Vaccine Data Despite HHS Funding Cut - Yahoo Finance
Moderna Stock Drops On HHS Funding Termination For Pandemic Flu Vaccine; Retail Turns Bearish By Stocktwits - Investing.com India
Trump administration cancels $766 million contract to develop mRNA-based flu vaccines - FOX 13 News Utah
Trump administration cuts $766 million in funding to Moderna for bird flu, pandemic vaccine projects - Times of India
Trump's HHS cancels Moderna's $590M bird flu vaccine award - Axios
Moderna Announces Update on Investigational Pandemic Influenza Program - USA Today
US cancels more $700 million funding for Moderna bird flu vaccine - WTVB
Moderna (MRNA) Reports Positive Interim Results for H5 Flu Vaccine Trial | MRNA Stock News - GuruFocus
HHS Cancels Moderna’s $590 Million Contract for Bird Flu Vaccine - Bloomberg
Moderna (MRNA) Faces Contract Cancellation by U.S. Health Department | MRNA Stock News - GuruFocus
Moderna Announces Update on Investigational Pandemic Influenza P - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):